Phase 1 Attention Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
Attention Deficit Hyperactivity DisorderBorderline Personality Disorder
Boehringer Ingelheim96 enrolled12 locationsNCT07001475
Recruiting
Phase 1Phase 2
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
Attention Deficit Hyperactivity Disorder
National Institute of Mental Health (NIMH)219 enrolled1 locationNCT05608434
Recruiting
Phase 1
The impact of Sulpiride (600mg; a dopamine antagonist) on behavioural and electrophysiological measures of visuospatial attention and inhibition
Inhibitory Control DeficitsSpatial Attention Deficits
Professor Mark Bellgrove50 enrolled1 locationACTRN12617000652370
Not Yet Recruiting
Phase 1
Effects of mild brain stimulation in children with attention deficit hyperactivity disorder (ADHD)
Attention Deficit Hyperactivity Disorder
University of Newcastle20 enrolled1 locationACTRN12614001331628
Withdrawn
Phase 1
Evaluation of the pharmacokinetics and safety of multiple once-daily doses of IPX233 in healthy adult volunteers
Attention Deficit Hyperactivity Disorder (ADHA)
Impax Laboratories, Inc20 enrolled1 locationACTRN12614000518662
Completed
Phase 1
Evaluation of the Pharmacokinetics of IPX233 Formulations in Healthy Volunteers
Attention Deficit Hyperactivity Disorder (ADHD)
Impax Pharmaceuticals,A Division of Impax Laboratories, Inc.20 enrolled1 locationACTRN12613001073796